Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 23, 2008, Pages 6273-6278

  Kung, Pei Pei ^a   Funk, Lee ^a   Meng, Jerry ^a   Collins, Michael ^a   Zhou, Joe Zhongxiang ^a   Catherine Johnson, M ^a   Ekker, Anne ^a   Wang, Jeff ^a   Mehta, Pramod ^a   Yin, Min Jean ^a   Rodgers, Caroline ^a   Davies II, Jay F ^a   Bayman, Eileen ^a   Smeal, Tod ^a   Maegley, Karen A ^a   Gehring, Michael R ^a  

^a PFIZER INC   (United States)

Author keywords

Dihydroxylphenyl amides; Hsp90; Inhibitor

Indexed keywords

DIHYDROXYLPHENYL AMIDE; HEAT SHOCK PROTEIN 90 INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING ASSAY; CANCER CELL CULTURE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG POTENCY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; STRUCTURE ACTIVITY RELATION;

AMIDES; AMINO ACIDS; ANTINEOPLASTIC AGENTS; COMBINATORIAL CHEMISTRY TECHNIQUES; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MOLECULAR CHAPERONES; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 55749083540     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.09.081     Document Type: Article

References (23)

1. Jolly C., and Morimoto R.I. J. Natl. Cancer Inst. 92 (2000) 1564
2. Maloney A., and Workman P. Expert Opin. Biol. Ther. 2 (2002) 3
3. Banerji U., O'Donnell A., Scurr M., Pacey S., Stapleton S., Asad Y., Simmons L., Maloney A., Raynaud F., Campbell M., Walton M., Lakhani S., Kaye S., Workman P., and Judson I. J. Clin. Oncol. 23 (2005) 4152
4. Goetz M.P., Toft D., Reid J., Ames M.M., Stensgard B., Safgren S., Sloan J., Athreton P., Vasile V., Salazaar S., Adjei A., Croghan G., and Erlichman C. J. Clin. Oncol. 23 (2005) 1078
5. Grem L., Morrison G., Guo X.-D., Agnew E., Takimoto C.H., Thomas R., Szabo E., Growchow L., Grollman F., Hamilton J.M., Neckers L., and Wilson R.H. J. Clin. Oncol. 23 (2005) 1885
6. Workman P. Cancer Lett. 206 (2004) 149
7. d is the dissociation constant for pGA = 240 nM.
8. Basso A.D., Solit D.B., Chiosis G., Giri B., Tsichlis P., and Rosen N. J. Biol. Chem. 277 (2002) 39858
9. Akt lum assay: non-small cell lung carcinoma cell line H1299 was cultured in DMEM + 10%FBS, 10,000 cells/well were cultured in 96-well plate. Compounds were added to each well starting at 10 μM with threefold serial dilution of 11 points of various concentration. Twenty-four hours post adding compounds, cell lysates were prepared and subjected to Luminex 100 system using the Beadlyte Akt/PKB kit-Upstate #46-605.
10. Grenert J.P., Sullivan W.P., Fadden P., Haysead T.A., Clark J., Mimnaugh E., Krutzsch H., Ochel H.-J., Schulte T.W., Sausville E., Neckers L.M., and Toft D.O. J. Biol. Chem. 272 (1997) 23843
11. Ghiosis G., Timaul M.N., Lucas B., Munster P.N., Zheng F.F., Sepp-Lorenzino L., and Rosen N. Chem. Biol. 8 (2001) 289
12. Yang Z.-Q., Geng X., Solit D., Pratilas C.A., Rosen N., and Danishefsky S.J. J. Am. Chem. Soc. 126 (2004) 7881
13. Dymock B.W., Barril X., Brough P.A., Cansfield J.E., Massey A., McDonald E., Hubbard R.E., Surgenor A., Roughley S.D., Webb P., Workman P., Wright L., and Drysdale M.J. J. Med. Chem. 48 (2005) 4212
14. Shen G., and Blagg B.S.J. Org. Lett. 7 (2005) 2157
15. Brough P.A., Aherne W., Barril X., Borgognoni J., Boxall K., Cansfield K.-M., Cheung J., Collins I., Davies N.G.M., Drysdale M.J., Dymock B., Eccles S.A., Finch H., Fink A., Hayes A., Howes R., Hubbard R.E., James K., Jordan A.M., Lockie A., Martins V., Massey A., Mattews T.P., McDonald E., Northfield C.J., Pearl L.H., Prodromou C., Ray S., Raynaud F.I., Roughley S.D., Sharp S.Y., Surgenor A., Walmsley D.L., Webb P., Wood M., Workman P., and Wright L. J. Med. Chem. 51 (2008) 196
16. Gopalsamy A., Shi M., Goals J., Vogan E., Jacob J., Johnson M., Lee F., Nilakantan R., Petersen R., Svenson K., Chopra R., Tam M.S., Wen Y., Ellingboe J., Arndt K., and Boschelli F. J. Med. Chem. 51 (2008) 373
17. Garozotti M., and Hamdan M. J. Chromatogr. B 770 (2002) 53
18. The work on optimization of compound 7 will be described in a latter manuscript.
19. The SAR was done with racemic compounds due to difficulty making chiral pure compounds.
20. Neckers L., Schulte T.W., and Mimnanugh E. Investig. New Drugs 17 (1999) 361
21. Clarke P.A., Hostein I., Banerji U., Stefano F.D., Maloney A., Walton M., Judson I., and Workman P. Oncogene 19 (2000) 4125
22. Clevenger R.C., and Blagg B.S. Org. Lett. 6 (2004) 4459
23. Sorgi K.L., Maryanoff C.A., McComsey D.F., and Maryanoff B.E. Org. Syn. 75 (1998) 215